Focus Partners Wealth Has $71 Million Stock Position in Abbott Laboratories $ABT

Key Points

• Focus Partners Wealth increased its stake in Abbott to 531,003 shares (a 2.4% lift), representing about $70.995 million per its latest SEC filing.
• Several analysts trimmed price targets in late January (mostly into the low‑$130s), but the stock's consensus rating remains a Moderate Buy with a consensus price target of $136.16.
• Abbott reported Q4 EPS of $1.50 (in line) and revenue of $11.46B (below expectations), issued FY2026 EPS guidance of 5.55–5.80, and declared a quarterly dividend of $0.63 (≈2.3% yield).

Focus Partners Wealth lifted its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 2.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 531,003 shares of the healthcare product maker's stock after acquiring an additional 12,355 shares during the period. Focus Partners Wealth's holdings in Abbott Laboratories were worth $70,995,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Brighton Jones LLC increased its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock valued at $648,000 after buying an additional 162 shares during the period. United Bank grew its position in Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after buying an additional 2,001 shares in the last quarter. Foundations Investment Advisors LLC increased its stake in Abbott Laboratories by 3.6% during the 2nd quarter. Foundations Investment Advisors LLC now owns 10,841 shares of the healthcare product maker's stock worth $1,475,000 after acquiring an additional 377 shares during the period. Finally, Tortoise Investment Management LLC increased its stake in Abbott Laboratories by 10.7% during the 2nd quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker's stock worth $108,000 after acquiring an additional 77 shares during the period. Institutional investors and hedge funds own 75.18% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Raymond James Financial cut their target price on Abbott Laboratories from $146.00 to $130.00 and set an "outperform" rating for the company in a research report on Friday, January 23rd. The Goldman Sachs Group dropped their price target on Abbott Laboratories from $152.00 to $140.00 and set a "buy" rating for the company in a research note on Friday, January 23rd. Piper Sandler cut their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an "overweight" rating for the company in a research report on Friday, January 23rd. Oppenheimer decreased their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an "outperform" rating on the stock in a report on Friday, January 23rd. Finally, Weiss Ratings cut shares of Abbott Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, January 26th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $136.16.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $109.93 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.06. The stock has a market capitalization of $191.03 billion, a P/E ratio of 29.55, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74. The stock has a fifty day moving average of $114.25 and a 200-day moving average of $123.65.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.50. The firm had revenue of $11.46 billion for the quarter, compared to analysts' expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The business's revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories's payout ratio is 67.74%.

Insider Buying and Selling at Abbott Laboratories

In related news, SVP Eric Shroff sold 709 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares of the company's stock, valued at $4,526,575.12. This represents a 1.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Mary K. Moreland sold 613 shares of the business's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 3,055 shares of company stock worth $353,097 over the last 90 days. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.